GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

GlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost two thirds of patients responded to the drug after an ...

There are also a host of other multiple myeloma drugs in the pharma pipeline – there are high hopes for drugs such as GSK’s belantamab mafodotin, an antibody-drug conjugate that produced ...

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, ...

The global cancer antibody drug conjugates market is characterized by a competitive landscape, with substantial development efforts targeting multiple cancers, including both solid tumors and ...